VCEL · Vericel Corporation

The thesis

Vericel's knee-cartilage implant MACI is still growing above 20% a year, and the 5 November 2026 report lifted full-year revenue guidance above what analysts expected. The fourth-quarter report settles the case by showing whether MACI reaches the roughly $102 million that management described on the call.

Third-quarter revenue rose 26% to $85.4 million, against a $77.948 million estimate reported by Benzinga. Management raised 2026 revenue guidance to $344–346 million from $330–340 million, per the company's 8-K. The shares closed at $54.62 on 6 November 2026, their highest close in 52 weeks.

The narrative is accelerating: management said MACI biopsy growth, the earliest measure of future implants, rose through each quarter of 2026, and the 5 November 2026 report drew target increases from Truist and HC Wainwright. The price already reflects much of this, so the next three months depend on demand holding through the seasonally largest quarter.

Bullish and bearish views on Vericel Corporation

The bull case on Vericel Corporation (VCEL), in brief: MACI growth has lasted six quarters. The bear case: The year depends on one quarter.

Bull case

• MACI growth has lasted six quarters. MACI revenue rose 21% to $67.4 million in the third quarter, the sixth straight quarter at 20% or more, per the 5 November 2026 earnings call. Full-year MACI guidance rose to $290–292 million from $284–290 million.
• The arthroscopic version is widening use. More than 25% of condyle procedures under 4 square centimeters used MACI Arthro in the third quarter, a level management called a record on the 5 November 2026 call. The company also reported record third-quarter biopsies, implants and surgeons in its 8-K.
• Profit is rising faster than revenue. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) rose 48% to $25.2 million, or 30% of revenue, per the 8-K. Full-year margin guidance rose to 28% from 27%, and quarterly net income rose 179% to $14.2 million.
• The balance sheet funds its own plans. Vericel held $235.6 million of cash and investments and no debt at 30 September 2026, per the 8-K.
• New markets extend the runway. Management sizes MACI Ankle at about 20,000 US patients a year and more than $1 billion, and the MASCOT study is activating sites and enrolling patients, per the 5 November 2026 call. A UK launch is targeted for the second half of 2027, subject to a reimbursement appraisal by the National Institute for Health and Care Excellence.
• Analysts moved targets well above earlier levels. Truist raised its target to $65 from $52, per Investing.com, having lowered it to $52 on 14 October 2026. HC Wainwright raised its target to $75 from $72 on 6 November 2026.

Bear case

• The year depends on one quarter. MACI revenue was $189.3 million over the first nine months, per the 8-K, and the call put the fourth quarter at about $102 million. CFO Joe Mara tied upside on the 5 November 2026 call to early December trends continuing, so a soft December would hit the largest quarter directly.
• Burn revenue is set to fall. Burn Care revenue jumped 52% to $18.0 million in the third quarter, per the 8-K, but the call implied about $12 million in the fourth. CEO Nick Colangelo said the company "can't control the number of catastrophic burns that occur," which makes Epicel revenue hard to predict.
• Gross margin has work left to do. Gross margin was 73% in the third quarter, unchanged from a year earlier, and about 73% over nine months, per the 8-K. Management kept its full-year guide at about 75%, which requires a strong fourth quarter.
• Stock-based compensation was $28.2 million over the same period.
• Chief Operating Officer Michael Halpin sold 10,000 shares at $40.24, per a Form 4 dated 18 June 2026.
• Competition is active abroad. Colangelo called MACI the clear market leader on the 5 November 2026 call, and also acknowledged other cartilage repair products from large medical-technology companies, including recent European launches.

Price setup

The shares closed at $54.62 on 6 November 2026, the 52-week high in adjusted daily closes, and rose 23.2% over three months. MarketBeat puts the intraday 52-week high at $55.60.

The move came in two sessions. MarketScreener reported the shares up more than 21% during 5 November 2026 and closing at $51.78, up 13.85%, on a day Benzinga said the Nasdaq fell over 3%. The shares then finished higher again on 6 November 2026.

The price is stretched against its averages. MarketBeat listed the 50-day moving average at $40.74 and the 200-day at $38.80 on 6 November 2026. The 14-day relative strength index, a momentum gauge conventionally read as overbought above 70, stands at 78.7.

The first level that matters is $49.32, the 12-month high MarketBeat reported on 4 November 2026, the day before results. Observable crowding consists of that gap above the moving averages, the insider sales and the rapid target increases. The next earnings report is months away, so it adds no near-term event pressure.

Catalysts, next 30 days

• 7 November to 7 December 2026: Company announcements and news searches through 7 November 2026 show no dated Vericel event in this window. Vericel presented at the Stephens investment conference on 20 November 2025, and no 2026 appearance has been announced.
• 31 December 2026: The fourth quarter closes. Mara linked upside to early December trends on the 5 November 2026 call, and about $3 million of procurement revenue from the Biomedical Advanced Research and Development Authority (BARDA) is expected in the quarter.
• ~25 February 2027, est.: Fourth-quarter report, a date Vericel has not announced. It tests the roughly $102 million MACI figure and the 75% full-year gross margin guide. Formal 2027 guidance is also outstanding; Mara said on the call that the company will start conservatively and that consensus is a reasonable starting point for revenue.

What would change the view

The case breaks if MACI growth falls below the 20% pace of the past six quarters. Full-year MACI revenue under the $290 million low end of guidance would show that. So would 2027 guidance that management itself places below the consensus it called a reasonable starting point on 5 November 2026.

A full-year gross margin clearly under the guided 75% would weaken the profit half of the case. Slower MACI biopsy growth in the fourth-quarter report would be the earliest sign of softer implants ahead.

On price, a daily close below $49.32 would put the shares back under the 12-month high that stood before the report. That would mean the market had withdrawn much of the reaction to the results.

What it trades with

Vericel's revenue depends on surgeon adoption of MACI, knee and cartilage procedure volumes, burn incidence and BARDA procurement. Procurement is planned at about $3 million in the fourth quarter and about $4 million in the first quarter of 2027, per the 5 November 2026 call.

The shares rose on 5 November 2026 while the Nasdaq fell over 3%, per Benzinga. One session is too small a sample to measure correlation. The view that company results will outweigh index direction over the next three months would be wrong if the shares fall in step with the Nasdaq through sessions that carry no Vericel news.